RxSight reports Q2 revenue decline, cuts 2025 guidance

ALISO VIEJO, Calif. - RxSight, Inc. (NASDAQ:RXST), a provider of customized vision technology for cataract surgery patients, announced preliminary second quarter 2025 revenue of approximately $33.6 million, representing a 4% decrease compared to the same period last year. The announcement comes as the company’s stock trades near its 52-week low of $12.38, having declined about 64% over the past six months. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions, suggesting potential for a technical rebound.

The company sold 27,380 Light Adjustable Lenses (LAL) during the quarter, a 1% decrease from the first quarter of 2025 but a 13% increase compared to the second quarter of 2024. Light Delivery Device (LDD) sales fell significantly, with only 40 units sold, down 45% from the previous quarter and 49% from the year-ago period.

RxSight’s installed base reached 1,084 LDDs as of June 30, a 34% increase from 810 units at the end of the second quarter of 2024.

In response to the underperformance, the company has revised its full-year 2025 guidance downward. Revenue is now expected to be between $120.0 million and $130.0 million, down from the previous range of $160.0 million to $175.0 million, representing a year-over-year decrease of 7% to 14%.

The company raised its gross margin guidance to 72-74% from the previous 71-73% range, while reducing its operating expense forecast to $145.0-$155.0 million.

"We are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices," said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, according to the press release.

The company reported preliminary cash, cash equivalents and short-term investments of $227.5 million as of June 30, a slight decrease from $229.3 million at the end of March. InvestingPro data shows RxSight maintains strong liquidity with a current ratio of 12.68 and holds more cash than debt on its balance sheet. While currently trading below its Fair Value estimate, investors can access detailed financial health metrics and 8 additional ProTips through InvestingPro’s comprehensive research report.

RxSight plans to announce complete, unaudited financial results for the second quarter on August 7, 2025. With analyst price targets ranging from $16 to $28, investors seeking deeper insights into RxSight’s valuation and growth prospects can access the full InvestingPro Research Report, part of the platform’s coverage of over 1,400 US stocks.

In other recent news, RxSight Inc. reported its first-quarter 2025 earnings, showing a smaller-than-expected loss with an earnings per share (EPS) of -$0.03, beating the forecasted EPS of -$0.20. Revenue for the quarter was $37.9 million, marking a 28% year-over-year growth, though it fell short of the expected $39.09 million. The company attributed its revenue growth to the strong performance of its Light Adjustable Lens (LAL) product, which accounted for 72% of total revenue. Wells Fargo upgraded RxSight’s stock rating from Equal Weight to Overweight, raising the price target to $25, citing the company’s significant early lead in the light adjustable lenses market. Meanwhile, Stifel maintained a Hold rating on RxSight, noting a shift in surgeon sentiment regarding the company’s LAL technology. This shift includes mixed feedback from surgeons about the technology, despite its previous reputation as a standout innovation. RxSight continues to focus on expanding its international market presence, with recent regulatory approvals in South Korea and anticipated approvals in the UK. The company remains optimistic about its growth potential, projecting a revenue range of $160 million to $175 million for the full year 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.